Illuminating the invisible
Innovative laser technology that reliably and non-invasively detects skin cancer
Luminoma will enable easy access to objective and precise skin cancer screening
A reliable diagnostic aid
The LumAssureTM will inform clinical assessment of skin lesions to provide assurance in biopsy decisions.
Rapid results
The test process will take seconds to perform, with results returned in 10 seconds—without compromising on precision.
Minimise false negatives
Our advanced Raman spectroscopy technology drastically reduces the risk of missing malignant lesions, ensuring patients swiftly receive the care they need without compromising on safety.
Grounded in truth
Backed by clinical research and confirmed by histopathology, Luminoma offers a solution that will provide an objective, scientific result that clinicians can trust.
2 in 3 fair-skinned New Zealanders and Australians will get skin cancer1
Skin cancer stands as the most common form of cancer, with over 5.5 million cases diagnosed annually in the U.S. alone. Yet, the journey to a definitive diagnosis is fraught with uncertainty – primary care physicians are typically a patient's first option for reviewing a suspicious lesion, yet many lesions can be challenging to assess, creating a risk of missing a cancer. The result? Unnecessary biopsies and specialist referrals, wasted healthcare resources, and delayed patient care.
Clinical diagnosis of skin cancer is challenging
Conventional methods rely on the clinician's experience and training to identify which clinically suspicious lesions should be referred for biopsy. These reviews can be challenging, leading to missed cancers as well as a high rate of unnecessary biopsies to confirm the clinical diagnosis. As a result, clinicians are increasingly over-referring to avoid missing cancers and manage litigation risk.
Liberal biopsy and referral practices are unsustainable
Up to 9 out of 10 referrals by primary care physicians for biopsy are benign. When focusing on melanoma, 25 to 30 biopsies are needed, on average, to find each case. Junior doctors can average over 50 biopsies per case.
An aging population is overloading dermatologists, even in the US, where wait times can reach 8 months. Delays and deferred access for priority cases is causing patient anxiety.
Biopsies can cause significant scarring
Suspicious lesions typically occur in areas with significant sun exposure, such as the face, back, and arms. Biopsies of these lesions can result in unsightly scarring.
The LumAssure™ desktop device and wand provides a recommendation in seconds
Luminoma is developing the LumAssure™, a portable, non-invasive diagnostic-aid that uses Raman spectroscopy to detect bio-molecular signatures in the skin – delivering a 99% sensitivity rate to avoid missing cancers whilst reducing unnecessary biopsies by 72%. With the LumAssure™, clinicians can confidently discern malignant from benign with a test that takes 10 seconds, reducing unnecessary referrals and biopsies.
Discover the future of skin cancer screening
Experience the power of Luminoma's innovative laser-based screening technology for accurate skin cancer detection.
Precision in prevention: Redefining skin cancer screening.
We are exploiting the powerful combination of Raman spectroscopy and machine learning to make skin cancer screening as objective and accessible as possible. We are dedicated to safely enhancing medical practice and improving patient outcomes by transforming the diagnostic pathway. The LumAssure™ promises to save lives by catching skin cancer in its earlier and more treatable stages.
FAQs
The LumAssure™ will be trained to identify the three most common forms of skin cancer; melanoma, basal cell carcinoma and squamous cell carcinoma. These three forms comprise over 99% of all skin cancer cases.
A positive test result indicates to a clinician that they should consider further investigation through a confirmatory biopsy.
The LumAssure™ will be able to differentiate between benign lesions such as different types of nevi and inflammatory dermatoses
The LumAssure™ will be suitable for use by both dermatologists and primary care physicians (also known as general practitioners) to assist with their diagnosis. It will not be suitable for use by patients themselves.
The measurement will take 10 seconds to perform and the results rapidly analysed afterwards.
A weak laser light is delivered to the skin lesion and the light collected back from the skin provides insight into the lesions molecular make up. It is non-invasive and completely painless.
Yes, the LumAssure™ will have a range of wand tips that are custom designed to be compatible with all areas of the body including ears, noses, inside of the mouth and the webbing between toes and fingers.
